Pharmacogenetic targeting of drugs for heart failure

Pharmacology and Therapeutics

Volumn 134, Issue 1, 2012, Pages 107-115

  Bristow, Michael R ^a,b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ARCA Biopharma   (United States)

Author keywords

Cardiovascular drugs; Drug development; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARDIOVASCULAR AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ISOSORBIDE DINITRATE; METOPROLOL;

DNA POLYMORPHISM; DRUG DEVELOPMENT; DRUG TARGETING; GENETIC VARIABILITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

DRUG DESIGN; HEART FAILURE; HEART VENTRICLES; HUMANS; STROKE VOLUME;

EID: 84857363880     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.01.002     Document Type: Review

References (55)

1. R. Aleong, G. Davis, W. Sauer, A.D. Robertson, and M.R. Bristow Prevention of atrial fibrillation by bucindolol is completely dependent on the Beta-1 389 Arg/Gly adrenergic receptor polymorphism Circulation 124 2011 A10438
2. N. Au, and A.E. Rettie Pharmacogenomics of 4-hydroxycoumarin anticoagulants Drug Metab Rev 40 2008 355 375
3. J.F. Beshai, R.A. Grimm, S.F. Nagueh, J.H. Baker 2nd, S.L. Beau, S.M. Greenberg, L.A. Pires, P.J. Tchou, and Rethin Q Study Investigators Cardiac-resynchronization therapy in heart failure with narrow QRS complexes N Engl J Med 357 2007 2461 2471
4. M.G. Bonini, K. Stadler, S.O. Silva, J. Corbett, M. Dore, J. Petranka, D.C. Fernandes, L.Y. Tanaka, D. Duma, F.R. Laurindo, and R.P. Mason Constitutive nitric oxide synthase activation is a significant route for nitroglycerin-mediated vasodilation Proc Natl Acad Sci 105 2008 8569 8574
5. A. Bonnardeaux, E. Davies, X. Jeunemaitre, I. Féry, A. Charru, E. Clauser, L. Tiret, F. Cambien, P. Corvol, and F. Soubrier Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension Hypertension 24 1994 63 69
6. M.R. Bristow Treatment of chronic heart failure with β-adrenergic receptor antagonists: A convergence of receptor pharmacology and clinical cardiology Circ Res 109 2011 1176 1194
7. M.R. Bristow, and W.R. Hiatt The FDA regulatory process for drug and genetic diagnostic test approvals Clin Transl Sci 1 2008 188 189
8. M.R. Bristow, H. Krause-Steinrauf, R. Nuzzo, C.-S. Liang, J. Lindenfeld, B.D. Lowes, B. Hattler, W.T. Abraham, L. Olson, S. Krueger, S. Thaneemit-Chen, J.M. Hare, M.J. Domanski, E.J. Eichhorn, P. Lavori, and R. Zelis Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial (BEST) Circulation 110 2004 1437 1442
9. 2C-adrenergic receptor polymorphism alters the norepinephrine lowering effects and therapeutic response of the beta blocker bucindolol in chronic heart failure Circ Heart Fail 3 2010 21 28
10. M.R. Bristow, L.A. Saxon, J. Boehmer, S. Krueger, D.A. Kass, T. De Marco, P. Carson, L. DiCarlo, D. DeMets, B.G. White, D.W. Devries, A.M. Feldman, and for the COMPANION Investigators Effect of cardiac resynchronization therapy with and without an implantable defibrillator on morbidity and mortality in advanced chronic heart failure: The COMPANION Trial N Engl J Med 350 2004 2140 2150
11. L. Chen, D. Meyers, G. Javorsky, D. Burstow, P. Lolekha, M. Lucas, A.B. Semmler, S.M. Savarimuthu, K.M. Fong, I.A. Yang, J. Atherton, A.J. Galbraith, W.A. Parsonage, and P. Molenaar Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol Pharmacogenet Genomics 17 2007 941 949
12. J.G.F. Cleland, J.-C. Daubert, E. Erdmann, N. Freemantle, D. Gras, L. Kappenberger, and L. Tavazzi The effect of cardiac resynchronization on morbidity and mortality in heart failure N Engl J Med 352 2005 1539 1549
13. A.H. Danser, M.A. Schalekamp, W.A. Bax, A.M. van den Brink, P.R. Saxena, G.A. Riegger, and H. Schunkert Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism Circulation 92 1995 1387 1388
14. A.H.J. Danser, C.A.M. van Kesteren, W.A. Bax, M. Tavenier, F.H.M. Derkx, P.R. Saxena, and M.A. Schalekamp Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts: Evidence for renin binding Circulation 96 1997 220 226
15. K.J. Ellis, G.A. Stouffer, H.L. McLeod, and C.R. Lee Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations Pharmacogenomics 10 2009 1799 1817
16. S. Erbs, S. Möbius-Winkler, A. Linke, V. Adams, N. Doll, S. Gielen, J.F. Gummert, F.W. Mohr, G. Schuler, and R. Hambrecht Both T-786C and G894T polymorphisms of endothelial nitric oxide synthase affect in-vitro endothelium-dependent relaxation of internal mammary artery rings from patients with coronary artery disease Eur J Cardiovasc Prev Rehabil 13 2006 826 831
17. S.A. Gayther, W. Warren, S. Mazoyer, P.A. Russell, P.A. Harrington, M. Chiano, S. Seal, R. Hamoudi, E.J. van Rensburg, A.M. Dunning, R. Love, G. Evans, D. Easton, D. Clayton, M.R. Stratton, and B.A. Ponder Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation Nat Genet 11 1995 428 433
18. H.T. Gold, M.J. Hall, V. Blinder, and B.R. Schackman Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer Cancer 115 2009 3858 3867
19. J.P. Kitzmiller, D.K. Groen, M.A. Phelps, and W. Sadee Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others Cleve Clin J Med 78 2011 243 257
20. M. Kupari, A. Hauteanen, L. Lankinien, P. Koskinen, J. Virolainen, H. Nikkila, and P.C. White Associations between human aldosterone sythase (CYP11B2) gene polymorphisms and left ventricular size, mass and function Circulation 97 1998 569 575
21. D. Kurnik, C. Li, G.G. Sofowora, E.A. Friedman, M. Muszkat, H.G. Xie, P.A. Harris, S.M. Williams, U.B. Nair, A.J. Wood, and C.M. Stein Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade Pharmacogenet Genomics 18 2008 895 902
22. C.P. Leeson, A.D. Hingorani, M.J. Mullen, N. Jeerooburkhan, M. Kattenhorn, T.J. Cole, D.P. Muller, A. Lucas, S.E. Humphries, and J.E. Deanfield Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function Circ Res 90 2002 1153 1158
23. S.B. Liggett, S. Cresci, R.J. Kelly, F.M. Syed, S.J. Matkovich, H.S. Hahn, A. Diwan, J.S. Martini, L. Sparks, R.R. Parekh, J.A. Spertus, W.J. Koch, S.L. Kardia, and G.W. Dorn 2nd A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure Nat Med 14 2008 510 517
24. S.B. Liggett, J. Mialet-Perez, S. Thaneemit-Chen, S.A. Weber, S.M. Greene, D. Hodne, B. Nelson, J. Morrison, M.J. Domanski, W.T. Abraham, J.L. Anderson, J.F. Carlquist, H.J. Krause-Steinrauf, L.C. Lazzeroni, J.D. Port, P.W. Lavori, and M.R. Bristow A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure Proc Natl Acad Sci 103 2006 11288 11293
25. A.S. Maisel, P. Krishnaswamy, R.M. Nowak, J. McCord, J.E. Hollander, P. Duc, T. Omland, A.B. Storrow, W.T. Abraham, A.H. Wu, P. Clopton, P.G. Steg, A. Westheim, C.W. Knudsen, A. Perez, R. Kazanegra, H.C. Herrmann, P.A. McCullough, and Breathing Not Properly Multinational Study Investigators Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure N Engl J Med 347 2002 161 167
26. D.A. Mason, J.D. Moore, S.A. Green, and S.B. Liggett A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor J Biol Chem 274 1999 12670 12674
27. D.M. McNamara, R. Holubkov, K. Janosko, R.A. Palme, J.J. Wang, G.A. MacGowan, S. Murali, W.D. Rosenblum, B. London, and A.M. Feldman Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure Circulation 103 2001 1644 1648
28. D.M. McNamara, R. Holubkov, L. Postava, K. Janosko, G.A. MacGowan, M. Mathier, S. Murali, A.M. Feldman, and B. London Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure J Am Coll Cardiol 44 2004 2019 2026
29. D.M. McNamara, S.W. Tam, M.L. Sabolinski, P. Tobelmann, K. Janosko, L. Venkitachalam, E. Ofili, C. Yancy, A.M. Feldman, J.K. Ghali, A.L. Taylor, J.N. Cohn, and M. Worcel Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: Results from the A-HeFT trial J Card Fail 15 2009 191 198
30. J. Mialet-Perez, D.A. Rathz, N.N. Petrashevskaya, H.S. Hahn, L.E. Wagoner, A. Schwartz, G.W. Dorn, and S.B. Liggett Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure Nat Med 9 2003 1300 1305
31. Y. Miyamoto, Y. Saito, N. Kajiyama, M. Yoshimura, Y. Shimasaki, M. Nakayama, S. Kamitani, M. Harada, M. Ishikawa, K. Kuwahara, E. Ogawa, I. Hamanaka, N. Takahashi, T. Kaneshige, H. Teraoka, T. Akamizu, N. Azuma, Y. Yoshimasa, T. Yoshimasa, H. Itoh, I. Masuda, H. Yasue, and K. Nakao Endothelial nitric oxide synthase gene is positively associated with essential hypertension Hypertension 32 1998 3 8
32. T. Münzel, A. Daiber, and A. Mülsch Explaining the phenomenon of nitrate tolerance Circ Res 97 2005 618 628
33. C. O'Connor, I. Anand, M. Fiuzat, J. Plehn, S. Gottlieb, M. Silver, J. Lindenfeld, A. Miller, M. White, S. Liggett, G. Davis, A. Robertson, M.R. Bristow, and P. Carson Additive effects of β1 389 Arg/Gly α2C 322-325 Wt/Del adrenergic receptor genotype combinations on adjudicated hospitalizations and death in the BEST trial J Cardiac Fail 14 2008 S69
34. M.A. Pacanowski, I. Zineh, R.M. Cooper-Dehoff, C.J. Pepine, and J.A. Johnson Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension Am J Hypertens 22 2009 748 753
35. D.R. Pfost, M.T. Boyce-Jacino, and D.M. Grant A SNPshot: Pharmacogenetics and the future of drug therapy Trends Biotechnol 18 2000 334 338
36. A. Quintás-Cardama, H. Kantarjian, J. Cortes, and S. Verstovsek Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond Nat Rev Drug Discov 10 2011 127 140
37. M.V. Raynolds, M.R. Bristow, E.W. Bush, W.T. Abraham, B.D. Lowes, L.S. Zisman, C.S. Taft, and M.B. Perryman Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy Lancet 342 1993 1073 1075
38. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson, R.J. Glynn, and J.U.P.I.T.E.R. Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
39. B. Rigat, C. Hubert, F. Alhenc-Gelas, F. Cambien, P. Corvol, and F. Soubrier An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels J Clin Invest 86 1990 1343 1346
40. A.D. Roses Pharmacogenetics in drug discovery and development: A translational perspective Nat Rev Drug Discov 7 2008 807 817
41. 1-adrenoceptors in isolated human atrial myocardium Br J Pharmacol 138 2003 386 392
42. U.I. Schwarz Clinical relevance of genetic polymorphisms in the human CYP2C9 gene Eur J Clin Invest 33 Suppl 2 2003 23 30
43. A.J. Sehnert, S.E. Daniels, M. Elashoff, J.A. Wingrove, C.R. Burrow, B. Horne, J.B. Muhlestein, M. Donahue, S.B. Liggett, J.L. Anderson, and W.E. Kraus Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol J Am Coll Cardiol 52 2008 644 651
44. K.M. Small, S.L. Forbes, F.F. Rahman, K.M. Bridges, and S.B. Liggett A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors J Biol Chem 275 2000 23059 23064
45. J.F. Solus, B.J. Arietta, J.R. Harris, D.P. Sexton, J.Q. Steward, C. McMunn, P. Ihrie, J.M. Mehall, T.L. Edwards, and E.P. Dawson Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population Pharmacogenomics 5 2004 895 931
46. B.B. Spear, M. Heath-Chiozzi, and J. Huff Clinical application of pharmacogenetics Trends Mol Med 7 2001 201 204
47. M.R. Taylor, D. Slavov, K. Humphrey, L. Zhao, J. Cockroft, X. Zhu, P. Lavori, M.R. Bristow, L. Mestroni, and L. Lazzeroni A pharmacogenetic effect of an endothelin-1 haplotype to bucindolol therapy in chronic heart failure Pharmacogenet Genomics 19 2009 35 43
48. S.G. Terra, K.K. Hamilton, D.F. Pauly, C.R. Lee, J.H. Patterson, K.F. Adams, R.S. Schofield, B.S. Belgado, J.A. Hill, J.M. Aranda, H.N. Yarandi, and J.A. Johnson Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy Pharmacogenet Genomics 15 2005 227 234
49. M. Tesauro, W.C. Thompson, P. Rogliani, L. Qi, P.P. Chaudhary, and J. Moss Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: Cleavage of proteins with aspartate vs. glutamate at position 298 Proc Natl Acad Sci 97 2000 2832 2835
50. L. Tiret, B. Rigat, S. Visvikis, C. Breda, P. Corvol, F. Cambien, and F. Soubrier Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels Am J Hum Genet 51 1992 197 205
51. D. Wang, H. Chen, K.M. Momary, L.H. Cavallari, J.A. Johnson, and W. Sadée Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement Blood 112 2008 1013 1021
52. H.L. White, R.A. de Boer, A. Maqbool, D. Greenwood, D.J. van Veldhuisen, R. Cuthbert, S.G. Ball, A.S. Hall, and A.J. Balmforth An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: A MERIT-HF sub-study Eur J Heart Fail 5 2003 463 468
53. J. Woodcock, and L.J. Lesko Pharmacogenetics-tailoring treatment for the outliers N Engl J Med 360 2009 811 813
54. I. Zineh, A.L. Beitelshees, A. Gaedigk, J.R. Walker, D.F. Pauly, K. Eberst, J.S. Leeder, M.S. Phillips, C.A. Gelfand, and J.A. Johnson Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension Clin Pharmacol Ther 76 2004 536 544
55. L.S. Zisman, K. Asano, D.L. Dutcher, A. Ferdensi, A.D. Robertson, M. Jenkin, E.W. Bush, T. Bohlmeyer, M.B. Perryman, and M.R. Bristow Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart Circulation 98 1998 1735 1741